Edition:
India

Halozyme Therapeutics Inc (HALO.OQ)

HALO.OQ on NASDAQ Stock Exchange Global Select Market

19.47USD
20 Jun 2018
Change (% chg)

-- (--)
Prev Close
$19.47
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
296,725
52-wk High
$21.47
52-wk Low
$11.43

Chart for

About

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex... (more)

Overall

Beta: 2.08
Market Cap(Mil.): $2,435.27
Shares Outstanding(Mil.): 141.92
Dividend: --
Yield (%): --

Financials

BRIEF-Halozyme Therapeutics Says CEO Helen Torley's 2017 Compensation Was $5.18 Mln ‍​

* HALOZYME THERAPEUTICS INC SAYS CEO HELEN I. TORLEY'S 2017 TOTAL COMPENSATION WAS $5.18 MILLION VERSUS $4.85 MILLION IN 2016 – SEC FILING‍​ Source text - https://bit.ly/2udFEM8 Further company coverage:

23 Mar 2018

BRIEF-Halozyme Reports Q4 Earnings Per Share $0.85

* REITERATED 2018 FINANCIAL GUIDANCE FOR NET REVENUE OF $115 MILLION TO $125 MILLION Source text for Eikon: Further company coverage:

21 Feb 2018

BRIEF-Halozyme Projects 25 To 30 Percent Enhanze Royalty Growth In 2018

* HALOZYME PROJECTS 25 TO 30 PERCENT ENHANZE ROYALTY GROWTH IN 2018

10 Jan 2018

Competitors

Earnings vs. Estimates